Cavers Greg's Form 4 filing
Helus Pharma Inc.HELP · filed Oct 1, 2026
- Accession no.
- 0000912282-26-001334
- Filed
- Oct 1, 2026, 8:13 PM ET
- Trade date
- Sep 29, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $38.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cavers GregCIK 0002116548 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 29, 2026 | Common Shares | PPurchaseAcquired | +3,000 | $12.91F1 | +$38,730 | 3,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Converted from Canadian purchase price of C$18.3157 using an exchange rate of C$1.4188 = US$1.00.
Referenced by the price of 1 transaction in Table I.